Accordingly, inhibition of GLI2 re-sensitizes ovarian tumors obtained from recurrent platinum-resistant patients to cisplatin39, 40, and also reverses taxane resistance in ovarian cancer41. This evidence concerns the gene GLI2 and ovarian neoplasm.